Goodwin advised BridgeBio Pharma on the matter. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Kyowa Kirin Co., Ltd (TSE:4151) announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Isomorphic Labs on its strategic research collaboration with Novartis. Isomorphic Labs has signed a strategic research collaboration with Novartis to discover small molecule therapeutics against...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Orionis Biosciences on the collaboration with Genentech. Privately held Orionis Biosciences announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised SonoThera, Inc. on the deal. SonoThera, Inc. announced its $60.75 million Series A financing round to support the continued development of SonoThera’s ultrasound-guided, nonviral,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Lacerta Therapeutics on the deal. Lacerta Therapeutics announced its AAV capsid licensing and research collaboration agreement with Prevail Therapeutics. As a part of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and...
You must be a Standard 1 Year member to access this content.
Goodwin advised Blueprint Medicines on the deal. Blueprint Medicines announced its strategic collaboration with Proteovant Therapeutics that will leverage Proteovant Therapeutics’ artificial intelligence-enhanced targeted protein degradation platform...
You must be a Standard 1 Year member to access this content.
Goodwin advised Tessera Therapeutics on the deal. Tessera Therapeutics announced its collaboration with Serotiny to engineer programmable Gene Writer proteins. Under the terms of the agreement, Serotiny...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Lyra Therapeutics, Inc. on the deal. Lyra Therapeutics, Inc. (Nasdaq: LYRA) announced its strategic partnership and exclusive license agreement with LianBio for the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Mirati Therapeutics, Inc. on the deal. Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced its collaboration and license agreement with Zai Lab Limited (NASDAQ:...
You must be a Standard 1 Year member to access this content.
